Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases

Overview of attention for article published in Cell, October 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

patent: 17 patents

f1000: 1 research highlight platform

Readers on

mendeley: 317 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 17 patents that reference this research output.

DIETHYL-[6-(4-HYDROXYCARBAMOYL-PHENYL-CARBAMOYLOXY-METHYL)-NAPHTHALEN-2-YL-METHYL]-AMMONIUM…

Grant EP-3858340-B1

European Patent Office

08 Apr 2026

A CLASS IIA HDAC INHIBITOR AND DECITABINE TO TREAT MYOPATHY

Application WO-2023078807-A1

World Intellectual Property Organisation (WIPO)

11 May 2023

Methods for inhibiting muscle atrophy

Grant US-11090313-B2

United States of America

17 Aug 2021

18-20 member bi-polycyclic compounds

Grant US-10954194-B2

United States of America

23 Mar 2021

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 13 additional patents.